Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions The recent price target increase for Biodesix, Inc.
(NASDAQ:BDSX) by Canaccord to $22 from $20 may have caught investors off guard, but it's a symptom of a larger phenomenon: the growing importance of diagnostic testing in healthcare.
A Diagnostic Revolution in Progress Biodesix' revenue growth is being driven by increased demand for its blood based diagnostics services, particularly in lung disease diagnosis.